F3

F3 Resumes Drill Program Targeting A1 and B1 Shears

Retrieved on: 
Dienstag, Mai 7, 2024
FUU, Electrical resistivity and conductivity, PLN, Nose, B1, JR, F3, Radioactive decay, Anomaly, Uranium mining

The program will test new targets generated from the 30-hole winter drilling program along the A1 and B1 systems.

Key Points: 
  • The program will test new targets generated from the 30-hole winter drilling program along the A1 and B1 systems.
  • High priority drill targets include both the A1 and B1 shear intersects with the large displacement reverse fault, the "nose" of the sandstone hosted and strongly graphitic basement wedge, as well as the area directly between the A1 and B1 shears as defined by new ground EM which is also highlighted by a resistivity anomaly.
  • We see the potential for the PLN property, in particular the A1 and B1 conductor system, to host additional uranium mineralization based on structure and alteration.
  • Follow-up ground EM and Resistivity will be carried out over gravity targets as appropriate, to further define distinct drill targets.

F3 Uranium to Present at the OTC Metals & Mining Virtual Investor Conference on April 30th

Retrieved on: 
Mittwoch, April 24, 2024
A1, F3, OTC, PLN, FUU, TSV, F4

KELOWNA, British Columbia, April 24, 2024 (GLOBE NEWSWIRE) -- F3 Uranium Corp (TSV: FUU) (OTCQB: FUUFF) (“F3” or “the Company”) is pleased to announce that Mr. Raymond Ashley, President, P.Geo.

Key Points: 
  • KELOWNA, British Columbia, April 24, 2024 (GLOBE NEWSWIRE) -- F3 Uranium Corp (TSV: FUU) (OTCQB: FUUFF) (“F3” or “the Company”) is pleased to announce that Mr. Raymond Ashley, President, P.Geo.
  • will be presenting at the OTC virtual conference on April 30, 2024 @ 11:00AM EST.
  • Ray will be discussing the new targets that the PLN winter drilling has generated for the upcoming summer drill program along the A1 and B1 shear zones, as well as the planned F4 spin-out.
  • F3 wishes to invite individual and institutional investors, as well as advisors and analysts, to attend online at VirtualInvestorConferences.com.

Hearty Bay Drilling Suggests Till Sampling May Lead to Source of Radioactive Boulders

Retrieved on: 
Donnerstag, März 21, 2024
VLF, Ice, F3, FUU, Uranium mining

Drill Program Suspended Due to Early Ice Road Closure

Key Points: 
  • The winter ice road which the Company employs to access the Hearty Bay drill sites was closed about one month earlier than usual.
  • Importantly, this suggests that it will be possible to use the subglacial till sampling method to trace the dispersion of uraniferous till under the lake, and thus directly back to the source of the historic Isle Brochet high grade boulder trains.
  • The discovery of this 2.3 m thick till under the lake provides strong support for additional sub glacial till sampling to ultimately lead directly to the source from which the radioactive boulder trains on Isle Brochet originate.
  • An inversion based structural interpretation will then be included for drill planning for the next program on the property for which the timing is being considered.

Sagimet Biosciences Reports Full Year 2023 Financial Results and Provides Corporate Updates

Retrieved on: 
Montag, März 25, 2024
Research, FASN, Fatty liver disease, Congress, Exercise, Progression-free survival, F2, Patient, SAN, Food and Drug Administration, F3, G&A, IPO, Obesity, IND, Acne, Bevacizumab, Glioblastoma, Fibrosis, Clinical trial, NASH, FDA, Drug development, Pharmaceutical industry

SAN MATEO, Calif., March 25, 2024 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (Sagimet, Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel fatty acid synthase (FASN) inhibitors designed to target dysfunctional metabolic and fibrotic pathways, today reported financial results for the full year ended December 31, 2023, and provided corporate updates.

Key Points: 
  • In January 2024, Sagimet sold 9,000,000 shares of its Series A common stock in an underwritten public offering and received $104.7 million in net proceeds.
  • In November 2023, Sagimet presented preclinical data evaluating denifanstat alone or in combination with semaglutide in mouse models of MASH at the 7th Obesity and NASH Drug Development Summit.
  • In October 2023, Sagimet’s license partner for China, Ascletis Bioscience Co. Ltd. (Ascletis), presented Phase 2 topline results at the European Academy of Dermatology and Venereology (EADV) Congress 2023 in Berlin, Germany.
  • In July 2023, Sagimet closed an upsized IPO of Series A common stock, at a public offering price of $16.00 per share.

Real’s Entrepreneurial-Centric Model Continues to Attract Top Producers From Across North America

Retrieved on: 
Dienstag, April 2, 2024
REIT, Residential Building & Real Estate, Other Technology, Technology, Construction & Property, Diamond, Growth, Match, Associate, F3, Family, Private label, Estate, Mint, Real estate

Augustine market by RealTrends last year, with home sales totaling $110 million in 2023.

Key Points: 
  • Augustine market by RealTrends last year, with home sales totaling $110 million in 2023.
  • A Certified Luxury Home Marketing Specialist, Stynes and her team of more than 20 agents serve the Richmond, Va., market.
  • The eight-agent team serves the North Carolina communities of Wilmington, Leland, Hampstead, Surf City, Topsail, Oak Island and Ocean Isle Beach.
  • The 17-agent team serves the Norfolk and Virginia Beach, Va., markets as well as North Carolina’s Outer Banks.

Liver-Assessment Tool Hepatoscope® Cleared for Use in U.S. and Europe Just as First Medication for MASH* Gains FDA Approval

Retrieved on: 
Dienstag, März 26, 2024
Software, Research, General Health, Medical Devices, Technology, Healthcare Reform, Science, Other Technology, FDA, Other Science, Health, Public Policy, Government, Diagnosis, Scripps Center, School corporal punishment, CE, Liver disease, Disease, Associate, Physician, F2, Risk, Cirrhosis, Patient, Syndrome, F3, Triage, Tool, Death, MASH, Fibrosis, LSM, Use, Multimedia, Hepatocellular carcinoma, Liver, Food, Medical imaging

This is a timely and exciting development in the fight against metabolism-related liver disease, which is on the rise globally.

Key Points: 
  • This is a timely and exciting development in the fight against metabolism-related liver disease, which is on the rise globally.
  • The economic burden attributed to effects of MASLD in the U.S. exceeds $100 billion annually.
  • “Medication that can reverse some of the worst impacts of MASH will be a huge help to our patients.
  • Questions of access matter more than ever,” he concluded, “as patients stand to benefit from these newer, more effective forms of treatment.”

Absolute Racing Enters Porsche in Sepang 12 Hours with GEEKVP

Retrieved on: 
Montag, März 4, 2024
Sri Lankan, Formula Renault, GP3 Series, Intelligence, TSS, European, Audi, FIA Formula 2 Championship, Absolute, F3, Eshan, Audi R8, FIA, Geek, EuroCup, GT4, Singapore Grand Prix, Porsche Carrera Cup, Shri, Partnership

The trio of Absolute Racing drivers,  while new to this particular race, bring with them a wealth of racing experience.

Key Points: 
  • The trio of Absolute Racing drivers,  while new to this particular race, bring with them a wealth of racing experience.
  • The son of Sri Lankan racing legend David Pieris, Eshan Pieris will be making his debut in the 12 Hours of Sepang.
  • Commenting on the third Absolute Racing-run entry in the race, Ingo Matter, Team Principal of Absolute Racing, stated, "I am really delighted that we are joining the 12 Hours of Sepang for the first time with the Porsche 911 GT3 R and in partnership with Geek.
  • It is going to be an epic weekend, and I am really looking forward to it.”
    Dorian Boccolacci added, "I am very happy to join Absolute Racing for the 12 Hours of Sepang.

Akero Therapeutics Reports Statistically Significant Histological Improvements at Week 96 in Phase 2b HARMONY Study

Retrieved on: 
Montag, März 4, 2024
Fibrosis, F3, Cirrhosis, EFX, Marie Cassidy, MASH, Biopsy, Patient, Risk, Pharmaceutical industry

SOUTH SAN FRANCISCO, Calif., March 04, 2024 (GLOBE NEWSWIRE) --  Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious metabolic disease marked by high unmet medical need, today released preliminary topline week 96 results from HARMONY, a Phase 2b study evaluating the efficacy and safety of its lead product candidate efruxifermin (EFX) in patients with pre-cirrhotic metabolic dysfunction-associated steatohepatitis (MASH), fibrosis stage 2 or 3 (F2-F3). The study previously met its primary endpoint of ≥1 stage improvement in fibrosis with no worsening of MASH after 24 weeks of treatment for both the 50mg EFX (41%) and 28mg EFX (39%) dose groups, compared to 20% for the placebo arm. At week 96, the response rates on this endpoint increased to 75% (p

Key Points: 
  • Specifically, the placebo-adjusted effect sizes for fibrosis improvement without worsening of MASH grew from 21% to 52% between week 24 and week 96 for 50mg EFX and from 20% to 22% for 28mg EFX.
  • Highly statistically significant results for 50mg EFX at week 96 are notable because (1) the study was not fully powered at week 96 and (2) the placebo rate increased rather than decreased.
  • Analysis of the evolution of responses between weeks 24 and 96 indicated not only broader fibrosis improvement without worsening of MASH but also sustained response, particularly at 50mg EFX.
  • Among those patients with available week 96 biopsies whose fibrosis improved at week 24, 92% and 83% of the 50mg and 28mg EFX groups remained responders, respectively, compared to 40% for placebo.

Zealand Pharma Announces Financial Results for the Full Year 2023

Retrieved on: 
Dienstag, Februar 27, 2024
DREAM, F2, F1, Overweight, Obesity, Weight loss, Part, F3, Human, Boehringer Ingelheim, BMI, NASH, Fatty liver disease, Zealand Pharma

In parallel, Zealand is planning a Phase 2b trial of petrelintide planned for initiation in the second half of 2024.

Key Points: 
  • In parallel, Zealand is planning a Phase 2b trial of petrelintide planned for initiation in the second half of 2024.
  • In February 2024, Boehringer Ingelheim and Zealand Pharma announced positive results from the Phase 2 trial of survodutide in metabolic dysfunction-associated steatohepatitis (MASH), previously known as nonalcoholic steatohepatitis (NASH).
  • In December 2023, Zealand submitted an NDA to the U.S. FDA for the treatment of adult patients with SBS dependent on parenteral support.
  • A recording of the event will be available following the call on the Investor section of Zealand’s website at https://www.zealandpharma.com/events/ .

Canadian GoldCamps Enters into LOI to Acquire up to 70% interest in Murphy Lake Property located in the Athabasca Basin, Saskatchewan

Retrieved on: 
Montag, Februar 26, 2024
LOI, Calendar, F3, A68, Athabasca Basin, Lease

The Property is located in the north-eastern corner of the Athabasca Basin, 30 km north-west of Orano's McLean Lake deposits, 5 km south of ISOEnergy's Hurricane Uranium Deposit and covers approximately 6.1 square kilometers of land.

Key Points: 
  • The Property is located in the north-eastern corner of the Athabasca Basin, 30 km north-west of Orano's McLean Lake deposits, 5 km south of ISOEnergy's Hurricane Uranium Deposit and covers approximately 6.1 square kilometers of land.
  • Upon the Company earning a 50% interest in the Property, both parties agree to participate in a joint venture for the further exploration and development of the Property, and, if deemed warranted, to bring the Property or a portion thereof into commercial production by establishing and operating a mine.
  • Upon the Company exercising the option, F4 shall receive a 2% net smelter royalty (“NSR Royalty”), provided that the Company shall be responsible only for the percentage of the NSR Royalty equal to its percentage interest in the Property.
  • Therefore, if the Company obtains the initial 50% interest, it shall be responsible for 50% of the NSR Royalty; and if the Company obtains the full 70% interest, it shall be responsible for 70% of the NSR Royalty.